Vimarsana
Biggest News Aggregation in the World

Page 8 - Weight Management Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Weight Management Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Weight Management Program Today - Breaking & Trending Today

Black Business Month Supporting Grand Rapids Black Businesses - Vimarsana News

Black Business Month Supporting Grand Rapids Black Businesses

Happy Black Business Month! Here are 10 Black owned businesses in Grand Rapids that you should be supporting year round!

Source: wgrd.com
ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2023 Earnings Call Transcript - Vimarsana News

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2023 Earnings Call Transcript

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2023 Earnings Call Transcript August 7, 2023 ReShape Lifesciences Inc. beats earnings expectations. Reported EPS is $-0.00108, expectations were $-1.79. Operator: Good afternoon, and thank you for joining the ReShape Lifesciences Second Quarter 2023 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications. […]

Source: yahoo.com
ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2023 Earnings Call Transcript - Vimarsana News

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2023 Earnings Call Transcript

Michael Miller: Good afternoon, and thank you for joining the ReShape Lifesciences second quarter 2023 earnings call.

SCVNews.com | Opinion/Commentary: Meet New CIF-SS Commissioner Mike West - Vimarsana News

SCVNews.com | Opinion/Commentary: Meet New CIF-SS Commissioner Mike West

Welcome to the 2023-2024 year!!! As I begin my tenure as the 10th commissioner of the CIF Southern Section, I would like the opportunity to introduce myself to those of you who do not know me.

Evidence Weighed for Suicide/Self-Harm With Obesity Drugs - Vimarsana News

Evidence Weighed for Suicide/Self-Harm With Obesity Drugs

As the EU looks into cases of suicidal thoughts and self-harm associated with the GLP-1 agonists semaglutide, and liraglutide, Novo Nordisk says it is confident of the risk-benefit profile of these agents.